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The use of immunotherapy (IT) in cancer has 
recently resulted in impressive responses. Yet, the 
usages of IT regimens, especially those involving 
cytokine therapies, have also resulted in the in­
duction of severe systemic toxicities often not pre­
viously characterized in their preclinical animal 
studies. Because such toxicities often require inten­
sive care management of patients, the causes for 
the discrepancies in observations between clin­
ical and preclinical toxicity merit further study.
Cancer has been considered a disease of aging, 
with persons over 65 accounting for over 60% 
of newly diagnosed malignancies (Balducci and 
Ershler, 2005). Consequences of aging include 
gradual decreases in immunological function, 
thymic involution leading to decreased naive 
T cell output, restriction within T cell repertoire 
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Aging is a contributing factor in cancer occurrence. We recently demonstrated that sys-
temic immunotherapy (IT) administration in aged, but not young, mice resulted in induction 
of rapid and lethal cytokine storm. We found that aging was accompanied by increases in 
visceral fat similar to that seen in young obese (ob/ob or diet-induced obese [DIO]) mice. 
Yet, the effects of aging and obesity on inflammatory responses to immunotherapeutics are 
not well defined. We determine the effects of adiposity on systemic IT tolerance in aged 
compared with young obese mice. Both young ob/ob- and DIO-generated proinflammatory 
cytokine levels and organ pathologies are comparable to those in aged ad libitum mice 
after IT, culminating in lethality. Young obese mice exhibited greater ratios of M1/M2 
macrophages within the peritoneal and visceral adipose tissues and higher percentages of 
TNF+ macrophages in response to CD40/IL-2 as compared with young lean mice. Macro-
phage depletion or TNF blockade in conjunction with CD40/IL-2 prevented cytokine 
storms in young obese mice and protected from lethality. Calorie-restricted aged mice 
contain less visceral fat and displayed reduced cytokine levels, protection from organ 
pathology, and protection from lethality upon CD40/IL-2 administration. Our data dem-
onstrate that adiposity is a critical factor in the age-associated pathological responses to 
systemic anti-cancer IT.
© 2014 Mirsoian et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/ 
by-nc-sa/3.0/).
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study seeks to establish the consequences of increased adipose 
tissue accumulation throughout aging upon IT­induced tox­
icities. Here, we find that adiposity results in a skewing toward 
increased levels of proinflammatory M1 macrophages within 
the peritoneal cavity and visceral adipose tissues that ultimately 
result in heightened production of proinflammatory cytokines, 
namely TNF, during strong immune stimulation with IT. 
Importantly, aged ad libitum (AL)–fed mice and young obese 
mice succumb to TNF­mediated pathological responses culmi­
nating in rapid lethality, which are prevented through caloric 
restriction in the aged or through either macrophage depletion 
or TNF blockade.
RESULTS
IT administration in the aged results in rapid lethal cytokine 
storm and is associated with increased accumulation  
of visceral adipose tissue
The combination IT regimen consisting of CD40 and IL­2 
(CD40/IL­2) has previously shown synergistic anti­tumor 
effects resulting in the regression of metastatic tumors in 
young (<6 mo) mouse models (Murphy et al., 2003). Re­
cently, we demonstrated that administration of the therapeu­
tic dose (high dose [HD]) of CD40/IL­2 into aged mice 
(≥15 mo) resulted in a heightened cytokine storm that prompted 
multi­organ damage and resulted in 100% lethality by day 2 
of treatment (Bouchlaka et al., 2013). To address whether the 
increased lethality was specific to this therapeutic dosage in 
the aged, we administered CD40/IL­2 at a lower dose (LD), 
less than half, into aged AL­fed mice. Consistent with our 
previous findings, treatment of aged mice with LD IT re­
sulted in 100% mortality by day 2 of treatment (Fig. 1 A) and 
demonstrated increased serum levels of proinflammatory cy­
tokines TNF, IL­6, and IFN­, indicative of a cytokine storm 
(Fig. 1 B). In addition, to ensure that the lethality observed in 
the aged mice was not IT regimen–specific, we administered 
an IT combination of CpG and IL­2 (CpG/IL­2) into young 
WT and aged AL mice. Confirming our previous findings, 
aged mice treated with CpG/IL­2 therapy incurred a similar 
cytokine storm that culminated in rapid lethality by day 3 
(Fig. 1, C–E), in contrast to young mice which exhibited lower 
levels of cytokines and demonstrated complete treatment tol­
erance (Fig. 1, C–E).
Normal aging is inherently associated with changes in body 
mass composition—specifically with decreases in muscle mass 
and increases in intra­abdominal visceral adiposity (Harris, 
2002). Equally, within our animal studies an observable differ­
ence between aged and young mice is noted in overall size, in 
particular increased waist circumference (Fig. 1 F). On average, 
aged mice weigh twice as much as young (Fig. 1 G). To deter­
mine whether the difference in size is due to increases in fat 
deposits, we sought to quantify differences in body mass and 
the presence of visceral adiposity. Young (<6 mo) and aged 
(≥15 mo) C57BL/6 mice were analyzed through magnetic 
resonance imaging (MRI) to quantify the presence of visceral 
adiposity. Aged mice exhibited markedly increased body mass 
indices and total visceral fat volumes in comparison with young 
diversity, increases in genomic instability, and increases in cel­
lular senescence (Campisi, 2013). However, despite the ma­
jority of patients being of this demographic, the overwhelming 
majority of preclinical studies are performed in young inbred 
mice. We recently demonstrated that treatment of young mice 
with a combination IT regimen consisting of agonistic mono­
clonal antibody to CD40 (CD40) given in conjunction with 
IL­2 resulted in synergistic anti­tumor effects and was well 
tolerated (Murphy et al., 2003). Yet, administration of the same 
regimen in an aged cohort resulted in 100% lethality within 
two days of treatment (Bouchlaka et al., 2013). Importantly, the 
mortality in the aged was perpetuated by an aberrant cytokine 
storm mirroring a systemic inflammatory response syndrome 
(SIRS), which resulted in multi­organ damage (Bouchlaka et al., 
2013). These systemic toxicities were closely representative of 
those previously noted clinically with FDA­approved immu­
nostimulatory IT therapeutics such as high­dose IL­2 and 
IFN­ (Lee and Margolin, 2011).
Aging is associated with a gradual decline in immunolog­
ical function but is also accompanied by the coincidence of 
a systemic, chronic, and low­grade proinflammatory response 
termed inflammaging that leads to increased systemic cyto­
kine levels, namely IL­1, IL­6, and TNF (Franceschi, 2007). 
Emerging data suggests that inflammaging may be influenced 
by age­associated changes in body mass composition such as 
decreased lean muscle mass, increased adiposity, and increases 
in overall body mass index (BMI; Franceschi et al., 2000). 
Whether adiposity plays a role in the generation of systemic 
toxicities or whether it is primarily an age­associated occur­
rence remains unknown.
Like aging, hallmark to the obese microenvironment is 
the development of a low­grade chronic “meta­inflammatory” 
state. Excess adiposity is associated with increased infiltration 
of macrophages and proinflammatory mediators such as den­
dritic cells, NK cells, and T cells into fat depots that ultimately 
results in environmental remodeling. Consequences include 
increased circulating levels of C­reactive protein (CRP), IL­6, 
leptin, and TNF (Ronti et al., 2006; Vázquez­Vela et al., 2008). 
Importantly, the immunomodulatory effects of increased adi­
pose tissue extends through the ability for both adipocytes and 
the stromal vascular fraction to express a variety of immunologi­
cally important surface receptors, such as the leptin receptor, 
IL­6 receptor, and both p55 and p75 TNF receptors (Ailhaud, 
2000). Systemic consequences of increased adiposity are also 
seen at distance sites through premature induction of aging­
associated changes such as thymic involution, which leads to 
the restriction of naive T cell output and ultimately restriction 
of the T cell repertoire (Yang et al., 2009).
Collectively, the field of IT has made great progress in the 
last decade toward the development of therapeutic candidates 
against cancer. Yet, these candidates have been met in the clinic 
with the induction of severe, often limiting, systemic toxici­
ties that hinder their usage. Additionally, given the rise of 
obesity within society, as well as the estimation that cancer is 
a disease primarily of the aged, using lean and young models 
may not accurately reflect patient outcomes. Therefore, this 
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were similar to young mice (Fig. 1, G–I). MRI scans of young 
(4 mo), middle­aged (9 mo), and aged (15 mo) mice that were 
either AL­fed or CR throughout life showed significant dif­
ferences in adipose accumulation over time (Fig. 1 I). We found 
that with increasing age, AL­fed mice have a proportional in­
crease in body fat content, whereas mice placed on a CR diet 
lack increased fat accumulation regardless of age. Aged CR 
mice show no significant difference in fat volume ratios to 
their middle­age and young counterparts, and remain similar 
to young AL mice (Fig. 1 I).
Caloric restriction in aged mice results in decreased 
accumulation of adiposity and protection  
from IT-induced toxicity
To examine the effect of adiposity and aging on the develop­
ment of systemic toxicities after IT, aged AL, aged CR, and 
young AL mice were administered IT or a control therapy 
mice (Fig. 1, G and I). These results indicate that aged mice are 
not only heavier and larger in size but that these size differences 
are attributed to increases in adipose tissue accumulation.
Adipose tissue is widely published to be a highly active 
metabolic organ with immune modulatory capabilities. To 
address whether in our aged AL­fed mice, who were allowed 
to freely access food, the increased adiposity noted was con­
tributory toward the development of IT­induced toxicities in 
the aged, we aimed to determine the effects of IT administra­
tion into an aged calorie­restricted (CR) cohort. CR mice are 
placed on a food restriction diet beginning at 14 wk of age 
and maintained throughout life. To ensure that age­matched 
CR aged mice contained a decreased accumulation of body 
fat in comparison with aged AL mice, we quantified total body 
weight and visceral fat through MRI (Fig. 1, H and I). CR 
mice weighed significantly less than AL aged mice and exhib­
ited a decreased presence of visceral adiposity to levels that 
Figure 1. Aged AL mice show increased 
proinflammatory cytokines, rapid lethality 
to LD IT, and display increased fat volume 
ratios in comparison to aged CR mice.  
(A) Ad libitum–fed C57BL/6 mice were treated 
with LD CD40/IL-2 or rIgG/PBS and survival 
was monitored, n = 5–8 mice/group. (B) Serum 
cytokines TNF, IL-6, and IFN- were measured 
day 2 by CBA after the start of CD40/IL-2 or 
rIgG/PBS therapy in aged AL mice, n = 3–5 
mice/group. (C) Young AL (3 mo) and aged AL 
(18 mo) mice were treated with CpG/IL-2 IT 
and survival was monitored, n = 5 mice/group. 
(D and E) Serum cytokine levels of TNF (D) and 
IL-6 (E) were measured by CBA on day 2 after 
the start of therapy, n = 5 mice/group.  
(F) Representative image of aged and young 
C57BL/6 mice showing size and waist circum-
ference. (G) Total body weight (left graph) and 
visceral fat weight (right graph), was mea-
sured for young (2 mo) and aged AL mice  
(20 mo), n = 5 mice/group. (H) Total body 
weight (left graph) or visceral fat (right graph) 
was measured in naive 15-mo-old C57BL/6 
mice on an AL or CR diet, n = 3–4 mice/group.  
(I) Visceral fat in young (4 mo), middle-aged  
(9 mo), and aged (15 mo) mice on either an AL 
(left) or CR (right) diet was evaluated by MRI. 
WS is indicative of water suppression, where 
fat is bright. FS is indicative of fat suppression, 
fat is dark/black. Data in all panels are repre-
sentative of one of at least five experiments 
with similar results. MRI scans are representa-
tive of one of at least three mice imaged per 
group with similar results. Survival analysis 
was plotted according to the Kaplan-Meier 
method, and statistical differences were deter-
mined with the log-rank test. Bar graph (mean 
value ± SEM) statistics were performed using 
either one-way or two-way ANOVA with  
Bonferroni post-hoc tests. ***, P < 0.001; **,  
P < 0.01; *, P < 0.05.
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succumb to mortality on day 2 of treatment (Fig. 2 G). How­
ever, 100% of aged CR mice placed on the HD amount of 
IT demonstrated complete protection from CD40/IL­2–
mediated lethality (Fig. 2 G). Collectively, these data suggest 
that increased body fat plays a critical role in the induction of 
systemic toxicities by IT. Increased adiposity played a critical 
role in the age­associated cytokine storm and subsequent organ 
pathologies after IT and calorie restriction diminished the de­
velopment of such toxicities conferring a protective effect that 
allowed for increased survival in the aged.
Increased adipose tissue accumulation through obesity, in the 
absence of age, results in IT-induced lethal cytokine storm
To further dissect the role of adipose tissue in the IT­associated 
inflammatory responses seen in aged mice, we next sought to 
determine the impact of adiposity, in the absence of age, as a 
possible cofactor. Young ob/ob mice (B6.Cg­Lepob/ob) are leptin­
deficient and therefore start exhibiting obesity by 3 wk of age. 
In comparison to age­matched young WT (2 mo) control mice 
placed on an AL diet (young AL), ob/ob mice have significantly 
higher body masses and weigh, on average, 2.5× greater 
(Fig. 3 A). MRI analysis of body fat content demonstrated 
(rIgG/PBS). IT resulted in increased lymphocytic infiltrates 
to the liver of aged CR and aged AL mice, in contrast to age­
matched control­treated mice (Fig. 2, A–C). To assess whether 
IT resulted in organ damage, livers and intestines were col­
lected on day 2 of treatment, the day of mortality in aged AL 
mice, and assessed for pathological changes. Importantly, livers 
and intestines from aged CR mice demonstrated significantly 
less inflammation and less necrosis in comparison with aged 
AL mice (Fig. 2, A and C). Serum analysis of alanine amino­
transferase (ALT) enzyme levels, a correlate of liver damage, 
showed a significant reduction in ALT levels in aged CR mice 
in comparison with aged AL mice (Fig. 2 B). Additionally, serum 
proinflammatory cytokine analysis of TNF (Fig. 2 D), IL­6 
(Fig. 2 E), and IFN­ (Fig. 2 F) resulted in all cytokines being 
significantly decreased in aged CR mice in comparison with 
the aged AL mice. These decreases in cytokine values were to 
levels that were either lower­than or as­low­as those in young 
AL mice that received IT (Fig. 2, D–F). To determine if these 
lower cytokine values during IT therapy would confer protec­
tion against IT­induced mortality, aged AL mice and aged CR 
mice were administered either LD IT or HD IT and monitored 
for mortality. Independent of treatment dose, aged AL mice all 
Figure 2. Calorie restriction in the aged confers protection by decreasing cytokine levels and IT-associated organ pathology, thereby  
allowing increased survival during IT. (A–C) Aged AL and age-matched aged CR mice (18 mo) were treated with HD CD40/IL-2 or rIgG/PBS; at day 2 
of IT, mice were sacrificed for histological analysis of livers (A) and intestines (C). Serum was collected on day 2 and assessed for ALT (B) levels, n = 3 mice/
group. Representative H&E images of liver and intestines (gut) for aged AL and aged CR groups. Bars, 200 µm. Asterisks represent steatosis and arrows 
denote areas of severe immune infiltration and/or necrosis. (D–F) Serum was analyzed day 2 after treatment for TNF (D), IL-6 (E), and IFN- (F). (G) Aged 
(18 mo) C57BL/6 mice on AL or CR diet were treated with either LD or HD of CD40/IL-2 and survival was monitored. Control groups received rIgG/PBS. 
All data panels are representative of one of four independent experiments with similar results for all panels. Survival analysis was plotted according to 
the Kaplan-Meier method and statistical differences were determined by using the log-rank test. Bar graph (mean value ± SEM) statistics were performed 
using one-way ANOVA with Bonferroni post-hoc test. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01.
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was comparable to the aged AL mice and significantly greater 
than the young AL (Fig. 3, C and D).
Because HD IT resulted in significant changes within the 
obese ob/ob mice, we next administered the lower dose (LD) 
of IT to young ob/ob, young age­matched AL mice, aged AL, 
and aged CR mice. Administration of LD IT still resulted in 
significant increases in TNF and IL­6 proinflammatory cyto­
kine levels within the young ob/ob that were not significantly 
different to the aged AL mice (Fig. 3, E and F). Both ob/ob and 
aged AL were significantly greater than both the young AL 
and aged CR mice, where CR in the aged led to significant 
down­regulation in both TNF and IL­6 cytokine production 
(Fig. 3, E and F). Although the young ob/ob and the aged AL 
mice displayed increased levels of IFN­, these levels were not 
significant among the groups (Fig. 3 G). Consistent with the 
increase in proinflammatory cytokines at day 2 of IT treatment, 
100% of young ob/ob mice succumbed to IT­induced lethality 
within 4 days of treatment in contrast to 100% survival in the 
that young ob/ob mice have higher total body fat content that 
is similar in accumulation to the aged mice, being deposited 
largely in the intra­abdominal cavity, in comparison with young 
AL mice (Fig. 3 B).
To determine if adiposity could solely induce toxic con­
sequences in aged AL, young ob/ob and age­matched young 
AL mice were treated with HD IT and at day 2 of treatment 
analyzed for the presence of immune­mediated organ patholog­
ical changes within the liver and intestines (Fig. 3, C and D). 
IT resulted in mild inflammatory infiltrates in young AL mice 
but resulted in moderate to severe inflammation in the ob/ob 
mice, which was comparable to the aged within the intestines 
(Fig. 3 D). Yet, analysis of IT­induced liver pathology was hin­
dered by the presence of extensive steatosis in ob/ob mice, re­
sulting in a paradoxical interference in determining the intensity 
of immune­mediated inflammatory liver damage (Fig. 3 C). 
IT resulted in both the intestines and liver displaying the most 
immune­mediated inflammatory damage within the ob/ob that 
Figure 3. Increased adiposity indepen-
dently of age results in systemic release of 
proinflammatory cytokines and organ pa-
thology after IT in young ob/ob (obese) 
and aged AL mice. (A) Body weights of naive 
young (2 mo) WT and young ob/ob C57BL/6 
mice, n = 6 mice/group. Representative pic-
tures of young-AL WT mice and obese ob/ob 
naive mice are shown. (B) Total fat content in 
naive young WT (2 mo), young ob/ob (2 mo), 
and aged (18 mo) C57BL/6 mice was visualized 
by MRI. Fat is bright. (C and D) Young AL (2 mo), 
young ob/ob (2 mo), and aged AL (18 mo) mice 
were treated with HD CD40/IL-2 and liver  
(C) and gut (D) were stained with H&E and 
scored for histopathology on day 2. Bars,  
200 µm. Arrows indicate areas of steatosis 
and/or immune cell infiltration and asterisks 
indicate patchy necrosis and/or fibrosis.  
(E–G) Young AL (2 mo), young ob/ob (2 mo), 
aged AL (18 mo), and aged CR (18 mo) were 
treated with LD CD40/IL-2 and serum was 
collected day 2 of treatment and analyzed by 
CBA for levels of: TNF (E), IL-6 (F), and IFN- 
(G), n = 3 mice/group. (H and I) Young AL (2 mo), 
young ob/ob (2 mo), aged AL (18 mo), and 
aged CR (18 mo) were treated with LD CD40/
IL-2 (H) or CpG/IL-2 (I) or rIgG/PBS control and 
survival was monitored. (J) Serum levels of TNF 
were measured on day 2 of CpG/IL-2 therapy 
by CBA. Data in all panels are representative of 
one of at least three experiments with similar 
results. MRI scans are representative of at 
least three mice imaged per group with similar 
results. Survival data were plotted using the 
Kaplan-Meier method and statistical differ-
ences were determined with the log-rank test. 
Bar graph (mean value ± SEM) statistics per-
formed using Student’s t test or one-way 
ANOVA with Bonferroni post-hoc tests. ***,  
P < 0.001; **, P < 0.01; *, P < 0.05.
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This data further supports that increased adiposity plays a 
crucial role in the induction of systemic toxicities after IT. 
These data are suggestive that not only does an aging environ­
ment result in lethal toxicities but toxicity may also be depen­
dent on the increase in fat accumulation as the young ob/ob 
mice succumb to cytokine storm induction and mortality after 
IT, similar to that observed in the aged mice.
IT toxicity is TNF- and M1 macrophage–dependent within 
the peritoneum and visceral adipose tissues
A hallmark of obesity is the increasing infiltration of macro­
phages into adipose tissues (ATMs) through the secretion of 
MCP­1 by adipocytes. Phenotypically, these macrophages are 
young WT cohort (Fig. 3 H). 100% of aged AL mice yielded 
to lethality from the IT by day 2 of treatment, whereas 100% 
of aged CR mice survived the entire regimen (Fig. 3 H).
The pathological and lethal response observed within the 
young ob/ob mice was not CD40/IL­2 IT administration 
specific. Young AL and age­matched young ob/ob mice were 
administered CpG in combination with HD IL­2 and, like­
wise, resulted in lethality of 75% of young ob/ob mice by day 5 
of treatment but resulted in complete tolerance by young 
AL mice (Fig. 3 I). CpG/IL­2 therapy led to significantly in­
creased levels of serum proinflammatory cytokine TNF in an 
analogous trend as CD40/IL­2 administration on day 2 of 
therapy (Fig. 3 J).
Figure 4. IT toxicity is TNF-dependent through M1 macrophage accumulation. (A–D) Young (2 mo) WT and young (2 mo) ob/ob mice were 
treated with either control rIgG/PBS or LD CD40/IL-2. Visceral adipose tissue and peritoneal lavages were collected on day 2 and assessed for the pres-
ence of macrophages identified as CD45+CD19F4/80+CD11b+. Ratio of M1/M2 macrophages (A), and total numbers (B) and percentages (C) of TNF- 
producing macrophages. Macrophages identified as M1 macrophages were characterized as CD206; M2 macrophages were gated as CD206+. (E–H) 
Young AL (2 mo) and young ob/ob (2 mo) were treated with either control or macrophage depleting clodronate liposomes before and during LD CD40/IL-2 
and survival was monitored; n = 5 mice/group. (F and G) On day 2, visceral adipose tissues and peritoneal lavages were collected and assessed for the 
percentages TNF+ macrophages (F and G) as characterized in experiments in A–D and serum TNF levels (H), n = 4 mice/group. (I–L) Young AL (2 mo) and 
young ob/ob (2 mo) mice were treated with either control hIgG/PBS or subcutaneous injection of 1.5 mg/0.1 ml etanercept before and during LD CD40/
IL-2 and survival was monitored (I), n = 5 mice/group. (J and K) On day 2, visceral adipose tissue and peritoneal lavages were collected and assessed by 
flow cytometry for the percentages of TNF+ macrophages (J and K) and serum TNF levels (L); n = 4 mice/group. Data in all panels are representative of one 
of at least three experiments with similar results. Survival data were plotted using the Kaplan-Meier method and statistical differences were determined 
with the log-rank test. Bar graph (mean value ± SEM) statistics performed using one-way ANOVA with Bonferroni post-hoc tests. **, P < 0.01; *, P < 0.05.
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(Fig. 4, I–L). Both macrophage depletion and co­treatment 
with etanercept during LD CD40/IL­2 resulted in complete 
protection of young ob/ob mice from lethality (Fig. 4, E and I). 
As expected, treatment with liposomal clodronate led to signif­
icantly decreased levels of TNF­producing macrophages within 
both the visceral fat and peritoneal lavages (Fig. 4, F and G), 
which significantly reduced systemic circulating serum levels 
of proinflammatory cytokine TNF (Fig. 4 H). Additionally, 
co­administration of LD CD40/IL­2 with etanercept did 
not reduce the percentages of TNF­expressing macrophages 
within the visceral fat or peritoneal cavity (Fig. 4, J and K) but 
mediated complete protection through an overall reduction 
in systemic TNF levels (Fig. 4 L).
Together, these data indicate that proinflammatory M1 
macrophages are the cellular mediator in the induction of IT 
toxicity, particularly through increased presence within the peri­
toneal and visceral adipose tissues. Importantly, these effects are 
TNF­dependent, as blocking TNF levels either through etan­
ercept administration or macrophage depletion resulted in com­
plete protection of young ob/ob mice from lethality.
Diet-induced obese (DIO) mice succumb to cytokine  
storm, organ pathology, and lethality similar to ob/ob  
and aged AL mice after IT
ob/ob mice are congenic for the spontaneous mutation in the 
OB gene, resulting in leptin hormone deficiency. To extend 
our findings, we generated young DIO mice. Mice were placed 
on a purified 60% fat diet to induce obesity beginning at 3 wk 
of age and were determined to be obese when weighing >40 g 
(DIO). Age­matched counterparts were placed on a matching 
predominately classically activated M1 cells that also express 
proinflammatory mediators IL­1, TNF, and IL­6 (Lumeng 
et al., 2007; Fujisaka et al., 2009). As such, we next sought to 
determine if increases in M1 macrophages within the perito­
neal cavity and visceral adipose tissues could account for the 
pathological increases in systemic TNF during IT administra­
tion. Young AL and age­matched young ob/ob mice were ad­
ministered LD CD40/IL­2. At day 2 of treatment, visceral 
adipose tissues and peritoneal lavages were phenotypically as­
sessed by flow cytometry for the presence of M1 (CD206) 
macrophages, M2 (CD206+) macrophages, and percentages 
of TNF­expressing macrophages. Consistently, young ob/ob 
mice demonstrated significant increases in M1 macrophage 
proportions during IT administration, whereas young AL mice 
were able to maintain consistent M1­to­M2 ratios (Fig. 4 A). 
Additionally, both the visceral adipose tissues and peritoneal 
lavages of ob/ob mice experienced significant increases in per­
centages of TNF­expressing macrophages as opposed to young 
AL mice (Fig. 4, B–D). Significant changes were not observed 
in the spleen of either young ob/ob or AL mice (unpublished 
data). This data, consistent with obesity literature, suggests that 
increases in adipose tissue accumulation within the visceral 
cavity may impact regulation of M1 and M2 macrophage ra­
tios that ultimately may affect TNF responses to immune stim­
ulation with immunotherapeutic regimens.
Given the increases in M1 macrophages within the obese 
mice and dysregulation observed with IT, young ob/ob and 
young AL mice were treated with LD CD40/IL­2 in conjunc­
tion with either liposomal clodronate for macrophage deple­
tion (Fig. 4, E–H) or etanercept (Enbrel) for TNF blockade 
Figure 5. DIO succumb to cytokine storm, 
organ pathology, and lethality similar to aged 
AL mice after IT. Young C57BL/6 mice were 
placed on a 60% fat diet starting at 3 wk of age 
to induce obesity (young DIO). Lean age-matched 
controls (young lean) were fed a 10% fat diet 
beginning at 3 wk of age. Young mice were ana-
lyzed at 5 mo of age, and aged AL mice were 
analyzed at 18 mo of age, n = 6 mice/group. Av-
erage body weight (A), representative pictures (B), 
and total fat content as measured by MRI (C) are 
shown for each group. (D–F) Young lean (5 mo), 
young DIO (5 mo), and aged AL (18 mo) mice 
were treated with HD CD40/IL-2 or rIgG/PBS. 
Serum was collected day 2 after the start of 
treatment and analyzed by CBA for levels of TNF 
(C), IL-6 (D), and IFN- (E) and survival was ana-
lyzed (F). Data in A–C are representative of one of 
at least three experiments with similar results and 
data in D–G are representative of one of at least 
four experiments with similar results. Survival 
data were plotted using the Kaplan-Meier method 
and statistical differences were determined with 
the log-rank test. Bar graph (mean value ± SEM) 
statistics performed using one-way ANOVA with 
Bonferroni post-hoc tests. ****, P < 0.0001;  
***, P < 0.001; **, P < 0.01; *, P < 0.05.
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were observed between young obese and aged AL mice, where 
aged mice die by day 2 but young obese mice die at day 4 of 
treatment. Therefore, although our data strongly demonstrates 
that adiposity plays a central role in the induction of toxicities, 
aging is also a likely key factor. Therefore, our findings high­
light the importance in considering both the status of aging 
and obesity of patients receiving systemic administration of stim­
ulatory IT regimens. It will be important to conduct studies 
dissociating the consequences of aging upon increased cytokine 
responsiveness, possibly through either investigating epigene­
tic modifications induced by the meta­inflammatory and/or 
inflammaging states associated with increased adipose accumu­
lation or whether aging is accompanied by changes in expres­
sion levels of various receptors that allow for a quicker response.
The development of IT regimens continues on a positive 
trajectory with increasing successes within a variety of can­
cers. Active IT has taken a greater comprehensive form focus­
ing on activating humoral and cell­mediated immunity, and 
these strategies have included antigen­specific vaccines (i.e., 
MART­1 vaccines), DC­based vaccines (i.e., Sipuleucel­T), 
inhibitors of checkpoint blockade (i.e., CTLA­4 and PD­1), 
and systemic stimulatory regimens through cytokine based 
therapies and application of agonistic antibodies (i.e., CD40, 
IFN­, and IL­2). Our data presented herein demonstrates 
that both young obese and aged AL mice succumb to rapid 
lethality during systemic administration of stimulatory thera­
pies. Our data strongly suggests that excess adiposity may be a 
prognostic factor in determining patient outcome and treat­
ment tolerance. However, additional studies need to be con­
ducted examining the effects of adiposity on the development 
of adverse reactions within other classes of IT regimens, such 
as checkpoint inhibitors.
Clinically, we hypothesize that taking into account patient 
BMI, adipose accumulation, and age may better modulate treat­
ment type choices as well as the inclusion of supportive thera­
peutics such as TNF blockade in conjunction with anti­cancer 
therapies that, overall, may increase patient survival and lead 
to greater anti­cancer responses. Follow­up investigations in 
tumor­bearing models merit further study.
MATERIALS AND METHODS
Animals and diets. Female young (2–5 mo old), middle­aged (9–12 mo old), 
and aged (15–22 mo old) C57BL/6 mice were purchased from Charles River 
or from the animal production area at the National Cancer Institute. Young 
female B6.Cg­Lepob/ob and young age­matched female WT control C57BL/6 
mice were purchased from The Jackson Laboratory at 8–12 wk of age.
DIO obese and control lean mice were generated from WT C57BL/6 
mice purchased at 3 wk of age from Charles River or from the animal produc­
tion area at the National Cancer Institute. Mice were placed on an open­source 
purified diet consisting of either 60% high­fat (D12492) or 10% low­fat 
(D12450J) constitution (Research Diets, Inc.). Age­matched mice were placed 
on either a high­fat or low­fat diet beginning at 3 wk of age for 16–20 wk 
and weighed weekly. Mice were deemed obese upon reaching a minimum of 
40 g of weight.
For studies comparing aged AL and CR dietary effects, both female aged 
CR and age­matched female AL­littermates (15–22 mo old) were purchased 
from the CR rodent colony at the National Institutes on Aging, National In­
stitutes of Health (NIH). In brief, mice were either raised through free access, 
AL, feeding on the NIH31 regular chow, or placed on a limited daily feeding 
purified diet that was 10% fat and served as lean controls. In­
creases in body mass were validated in DIO mice before IT 
administration (Fig. 5, A–C). DIO mice displayed increases in 
overall body weight and size (Fig. 5, A and B). MRI analysis 
of body fat content showed increased total body fat accumu­
lation, largely as increased visceral fat, in young DIO mice that 
was similar to the aged AL mice (Fig. 5 C).
Confirming our previous findings, DIO mice treated with 
HD CD40/IL­2 displayed increased serum TNF, IL­6, and 
IFN­ levels compared with age­matched young mice on a 
10% fat diet after IT administration (Fig. 5, D–F). The increases 
in proinflammatory cytokines in DIO mice were lower, yet not 
significantly so, than aged mice after IT (Fig. 4, C–E). Young 
DIO mice started succumbing to IT lethality at day 3 of treat­
ment (>60%), and <40% were still alive by day 4 (Fig. 5 G).
Together, these results suggest that adipose tissue is a criti­
cal component to the development of systemic cytokine storm 
and lethality after IT. Yet, due to the observation that treatment 
of DIO mice did not result in 100% of mice succumbing to 
lethality, aging itself may also likely contribute to the overall 
heightened inflammatory responses incurred by IT.
DISCUSSION
After initiation of strong immune stimulation with IT, we 
show that both young obese and aged AL mice demonstrate 
increased levels of adiposity, which led to aberrant increases in 
both TNF and IL­6 levels that ultimately resulted in multi­
organ damage. Similar to aging, obesity has been shown to be 
immunomodulatory, where the cross talk between adipocytes 
and macrophages is thought to lead toward the development 
and perpetuation of a meta­inflammatory state through con­
tinual NF­B activation, which is currently hypothesized to 
be responsible for the induction of metabolic diseases. A study 
conducted by Spaulding et al. (1997) examined the effects of 
age and calorie restriction on the production of TNF and IL­6 
in resting mice and demonstrated that serum levels of both 
cytokines were significantly higher in aged mice in compari­
son to young, and yet aged mice subjected to long­term calo­
rie restriction resulted in TNF and IL­6 serum levels that 
were comparable to the young mice. These findings lend sup­
port to the protective effects seen within our studies in the 
aged CR cohort administered IT.
Importantly, the data presented here demonstrate the need 
for using age and body fat content as variables in preclinical 
assessment of therapeutics and modeling diseases, such as can­
cer. However, the vast majority of inbred mouse studies are 
housed in specific pathogen­free colonies where normal aging 
may result in higher body fat content and yet less immune 
challenge from pathogens making them more susceptible to 
proinflammatory responses and toxicities after immune thera­
pies. It will therefore be important that future studies ascer­
tain responses in mice that have been exposed to pathogens 
and immune challenges as they age.
Furthermore, our data demonstrate that an obese phenotype 
resulted in lethal consequences that were ameliorated through 
calorie restriction in the aged. Also, differences in lethality 
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Murine macrophage studies. On day 2 of treatment, murine macrophages 
were isolated from either the peritoneal cavity or visceral adipose tissue. For 
peritoneal lavages, 4 ml of cold PBS was injected into the peritoneal cavity 
of each mouse and then aspirated. Lavages were spun down at 1,200 rpm for 
5 min and the resulting pellet was resuspended in RF10c media and plated 
for flow cytometry staining.
The stromal vascular fraction of visceral adipose tissues was collected day 
2 of treatment. Adipose tissues from the visceral cavity (gonadal) were col­
lected and then incubated for 60 min in a digestion solution consisting of 
2 mg/ml type IV collagenase (Sigma­Aldrich) dissolved fresh in a 2% BSA in 
PBS solution. After incubation samples were centrifuged at 1,200 rpm for 
5 min for layer separation of the stromal vascular fraction from adipocytes. 
The resulting stromal vascular fraction was then removed, resuspended into 
a single cell suspension, counted, and plated for flow cytometry staining.
Flow cytometry analysis of macrophages. Single cell suspensions from 
the peritoneal lavages and visceral adipose tissues were plated in RF10c media 
with the addition of GolgiPlug (containing Brefeldin A) and GolgiStop (con­
taining Monensin) Protein Transport Inhibitors (BD) according to manufac­
turer’s protocols. Plates were incubated for 9 h at 37°C and 5% CO2.
After incubation, cells were washed with PBS and stained for flow analy­
sis. Single cell suspensions were labeled with Fc block (purified anti–mouse 
CD16/32; BD) for 10 min, followed by labeling with antibodies for 20 min 
at 4C. Cells were washed twice with a staining buffer consisting of 5% FBS 
(Gemini Bio­products) in DPBS (Corning). For intracellular staining, the 
Cytofix/Cytoperm kit (BD) was used per manufacturer’s protocols. After 
staining, cells were analyzed using a custom configured Fortessa cytometer, 
and by using FACSDiva software (BD). Data were analyzed using FlowJo 
software vX (Tree Star). Antibodies used to distinguish macrophages were: 
PB­conjugated anti–mouse CD45, BV711­conjugated anti–mouse CD11b, 
BV605­ and PE­conjugated anti–mouse CD206, BV785­conjugated anti–
mouse CD19, APC­conjugated anti–mouse F4/80, and PE­Cy7–conjugated 
anti–mouse TNF (BioLegend).
Serum cytokine bead array. Serum levels of TNF, IFN­, and IL­6 were 
quantified by multiplex measurement using the Cytometric Bead Array 
(CBA; BD) kit as described previously (Bouchlaka et al., 2013). In brief, 
serum samples and standards were incubated for 1 h at 25°C with a bead 
mixture containing bound antibodies to TNF, IFN­, and IL­6 according to 
manufacturer’s instructions. Samples and standards were resuspended in wash 
buffer and analyzed by flow cytometry. Data were acquired on a custom­
configured Fortessa cell analyzer using FACSDiva software (BD) and analyzed 
using FlowJo software (Tree Star). Each sample was analyzed in triplicate. 
Upon analysis of raw data, the mean fluorescent intensities (MFIs) of each 
bead cluster were quantified. Where indicated in the figures, protein concen­
trations were extrapolated relative to a standard curve created by serial dilu­
tion of the mouse positive control cytokine.
Colorimetric liver enzyme assay. Serum ALT was quantified using the 
ID Labs ALT Enzymatic Assay kit (ID Labs Biotechnology Inc.) as previously 
described (Bouchlaka et al., 2013). Colorimetric determination of ALT levels 
was performed by reading the absorbance of each well at 340 nm on a plate 
reader (VERSAmax turntable plate reader). The concentration of ALT (U/liter) 
schedule with the NIH31­fortified chow. CR is initiated at 14 wk of age at 
10% restriction, increased to 25% restriction at 15 wk, and to 40% restriction 
at 16 wk of age where it is maintained throughout the life of the animal. In­
formation on survival curves, food intake curves, and body weights of the 
NIA strains has been previously published (Turturro et al., 1999).
All experimental mice were housed in the Animal Facilities at the Uni­
versity of California, Davis under specific pathogen­free (SPF) conditions. 
For the comparison in fat volume ratios, young, middle­aged, and aged AL 
and CR mice were ordered and sent to the National Institute on Aging for 
MRI analysis and also housed under SPF conditions. All of the animal proto­
cols were approved by the Institutional Animal Care and Use Committees of 
both institutions. Body weights were also measured for several mice at differ­
ent ages and on dietary regimens. Mice were euthanized by CO2 asphyxia­
tion and the visceral fat pads (mesenteric, gonadal, and renal) were collected 
and weighed together for each mouse to determine the visceral fat weight.
Reagents. The agonistic anti–mouse CD40 antibody (clone FGK115B3) 
was generated via ascites production in our laboratory as previously described 
(Murphy et al., 2003; Bouchlaka et al., 2013). The endotoxin level of the 
CD40 was <1 endotoxin unit/mg of antibody as determined by a quantita­
tive chromogenic limulus amebocyte lysate kit (QCL­1000; Bio Whittaker). 
Recombinant human IL­2 (rhIL­2; TECIN Teceleukin) was provided by the 
National Cancer Institute (NCI). Murine CpG ODN 1826 was purchased 
from InvivoGen. All were injected i.p.
Schedule of CD40/IL-2 and CpG/IL-2 IT treatments. Mice were 
treated with agonist CD40 antibody and rhIL2 as previously described 
(Murphy et al., 2003; Bouchlaka et al., 2013). CD40 or CpG was adminis­
tered daily for a total of 5 consecutive days (days: 0, 1, 2, 3, and 4) and IL­2 
was administered twice a day for a total of 4 d (days: 1, 4, 8, and 12). Control 
mice received rat IgG (rIgG; Jackson ImmunoResearch Laboratories, Inc.) 
and PBS (Cellgro). Survival was monitored daily. An HD or LD of CD40/
IL­2, or HD CpG/IL­2, was administered as follows on the same scheduling 
pattern as previously described (Bouchlaka et al., 2013): HD CD40/IL­2, 
mice received 80 µg of agonist CD40 and 106 IU of IL­2 in 0.2 ml PBS i.p.; 
control mice received 80 µg rIgG in PBS; LD CD40/IL­2, mice received 
40 µg of agonist CD40 and 4 × 105 IU of IL­2 in 0.2 ml PBS i.p; control 
mice received 40 µg rIgG in PBS; CpG/HD IL­2, mice received 100 µg CpG 
ODN 1826 (InvivoGen) and 106 IU of IL­2 in 0.2 ml PBS i.p.
Macrophage depletion and TNF blockade with etanercept (Enbrel). 
In some experiments, mice were in vivo depleted of macrophages using lipo­
somal clodronate or control­loaded liposomes (Encapsula NanoScience) be­
fore and during IT administration, as previously described (Bouchlaka et al., 
2013). For experiments where mice were euthanized by day 2 of treatment, 
0.2 ml per dose was injected i.p. of either clodronate or control liposomes on 
days 2 and 0. For all survival experiments, clodronate or control liposomes 
were administered on days 2, 0, 2, and 4.
TNF blockade was preformed through in vivo subcutaneous injection 
of 1.5 mg/0.1 ml etanercept (Enbrel) on days 1 and 1 for experiments where 
mice were euthanized on day 2 of IT therapy. For all survival experiments, 
etanercept was administered on days 1, 1, 3, 7, and 9.
Table 1. Grading of acute liver damage
Global assessment Criteria
0: None No portal inflammation
I: Minimal/indeterminate Portal inflammatory infiltrate is in a minority of the portal triads, which is minimal
II: Mild Inflammatory infiltrate in 50% of the triads, which is generally mild, and confined within the portal spaces
III: Moderate Inflammatory infiltrate, expanding most or all of the triads, and associated with mild interface and lobular activity
IV: Severe As above for moderate, with spillover into periportal areas and moderate to severe perivenular inflammation that 
extends into the hepatic parenchyma and is associated with perivenular hepatocyte necrosis
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normal body temperature using warm air. Mice were inserted into the scan­
ner in a head­first prone orientation. Spin­echo T1­weighted images were 
obtained through the mouse body (neck­to­base of the tail) using a 72­mm 
linear volume coil. Scan sequence parameters were the following: TR 1,000 ms, 
TE 15 ms, and 2 averages. The field of view was 7.7 × 3.85 × 2.0 cm, with a 
matrix size of 256 × 128 × 40. The corresponding voxel size was 0.3 × 0.3 × 
0.5 mm. Images were acquired using ParaVision 5.0 software. After acquisi­
tion, images were transferred into Invenon Research Workplace 4.0 software 
(Siemens Preclinical) allowing fat to be displayed with high intensity (white).
Statistical analysis. Statistical analyses were performed using Prism soft­
ware (GraphPad Software Inc.). Data were expressed as mean ± SEM. For 
analysis of three or more groups, a nonparametric ANOVA test was per­
formed with a Bonferroni post­hoc test. Analysis of differences between two 
normally distributed test groups was performed using the Student’s t test. 
Non­parametric groups were analyzed with the Mann­Whitney test. Welch’s 
correction was applied to datasets with significant differences in variance be­
fore Student’s t test.
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